News

AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...
Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...
AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The ...
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...
Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...
Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndrome: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This reports provides a data-driven overview ...
Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...
EMA recommends marketing authorization to Cordex Biologics’ new stem cell therapy, Zemcelpro to treat patients with blood cancers: Amsterdam, The Netherlands Monday, June 23, 20 ...
The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...